ELOCTA
SEWEDISH ORPHAN BIOVITRUM
Identification
- Active ingredient (INN)
- EFMOROCTOCOG
- Internal code
- 12 J 212
- Country of Origin
- Sweden
- Pharmaceutical form
- Powder for Injectable Sol.
- Prescription List
- Highly Regulated (List I)
- Packaging
- b/1 seringue
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Indications
Used to prevent, treat and reduce the incidence of hemophilia a.
Associated Conditions
Use under medical supervision: pregnancy and breastfeeding, given the possibility of adverse effect on the foetus.
The body may produce anti-warming objects as an immune reaction, thereby reducing the therapeutic effect of the drug.
The patient must be monitored if symptoms of the formation of these antibodies, such as the non-highness of the eighth factor in the blood or the continuation of the bleeding after the medication is given, are present.
Mechanism of Action
He's a copy of the eighth clotting agent, produced by the remodelled DNA technology.
He activates the tenth clotting agent in collaboration with the activated ninth clotting agent and then the tenth activated clotting agent converts prothrombin to thrombin, which converts phenogen to febrin, and with the thirteenth clotting agent, it is a constant clot.
Do you have questions on this subject? Ask Sina, artificial intelligence to answer all your medical questions.
Write your question here, Sina, prepare the answer for you.